GeneDx Holdings Corp. saw a significant price drop of 13.61% as it crossed below its 5-day SMA.
The company has formed a strategic partnership with Komodo Health to leverage Komodo's Healthcare Map®, aiming to create a comprehensive longitudinal dataset for rare diseases. This collaboration is expected to enhance the visibility into diagnosis, management, and treatment of rare diseases, ultimately driving biopharma innovation. GeneDx Infinity™, the world's largest rare disease genomic dataset, will play a crucial role in this initiative, providing a richer evidence base for research.
This partnership positions GeneDx to accelerate its growth in the genetic testing market, particularly in the rare disease sector, which is increasingly important for healthcare innovation.
Wall Street analysts forecast WGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 171.43 USD with a low forecast of 155.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast WGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 171.43 USD with a low forecast of 155.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 95.290
Low
155.00
Averages
171.43
High
200.00
Current: 95.290
Low
155.00
Averages
171.43
High
200.00
Canaccord
Buy
maintain
$170
2026-01-07
Reason
Canaccord
Price Target
$170
AI Analysis
2026-01-07
maintain
Buy
Reason
Canaccord maintains a Buy rating and $170 price target on shares of GeneDx after the company announced GenomeDx Prenatal, a phenotype-informed, trio-based test intended for pregnancies with fetal anomalies identified through ultrasound, which will be available for order beginning in February. GenomeDx Prenatal is differentiated given it is whole genome sequencing-based and positions GeneDx to effectively enter an attractive market, the analyst tells investors in a research note.
Canaccord
Buy
maintain
$160 -> $170
2025-12-22
Reason
Canaccord
Price Target
$160 -> $170
2025-12-22
maintain
Buy
Reason
Canaccord raised the firm's price target on GeneDx to $170 from $160 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for GeneDx.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for WGS
Unlock Now
Piper Sandler
David Westenberg
upgrade
$140 -> $160
2025-11-10
Reason
Piper Sandler
David Westenberg
Price Target
$140 -> $160
2025-11-10
upgrade
Reason
Piper Sandler analyst David Westenberg raised the firm's price target on GeneDx to $160 from $140 following quarterly results. The firm keeps an Overweight rating on the shares.
Guggenheim
Buy
upgrade
$115 -> $170
2025-10-29
Reason
Guggenheim
Price Target
$115 -> $170
2025-10-29
upgrade
Buy
Reason
Guggenheim raised the firm's price target on GeneDx to $170 from $115 and keeps a Buy rating on the shares following what the firm calls out as another quarter of whole exome and genome growth, strong average selling prices, and gross margin improvements. With "a large beat and even larger guidance raise," the firm does not believe management intended to signal a move to negative EPS despite management's comments on 2026 operating expenses, the analyst added.
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
